BMI ≥30 or BMI ≥27 with comorbidity.
Primary FDA-labeled indication for Wegovy and Zepbound.
GLP-1 therapy is now first-line pharmacotherapy for chronic weight management per multiple specialty society guidelines.
Five minutes. Free. No pressure.